Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Gb002
Seralutinib

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Vseobecna Fakultni Nemocnice V Praze
II. interní klinika kardiologie a angiologie VFN a 1. LF UK Centrum pro plicní hypertenzi
Prague, Czechia
Justus-Liebig-Universitaet Giessen
Universitaetsklinikum Giessen und Marburg GmbHPneumologie,Nephrologie und Gastroenterologie
Gießen, Germany
Thoraxklinik Heidelberg gGmbH
Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg Zentrum für pulmonale Hypertonie
Heidelberg, Germany

Sponsor: GB002 Inc.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.